MedTrace Logo

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

NCT01968265 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2015-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCCRRx in combination with metformin versus placebo + metformin

Conditions

Interventions

DRUG

ISIS-GCCRRx

3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin

DRUG

Placebo

3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin

Sponsors & Collaborators

  • Ionis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-01-31
Completion
2015-05-31

Countries

  • Canada
  • Romania
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968265 on ClinicalTrials.gov